The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Accumulation of AS either due to multiplication of SNCA locus [33], proteasomal defects [42], or mutation in AS gene [24, 41, 49], may also enhance formation of DOPAL-triggered oligomers and aggregates of AS.”
BackgroundAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · cited 3×
“These results are consistent with cell culture data supporting the view that AS oligomers, and not the large AS aggregates, trigger neuronal cell death [1].”
BackgroundResultInfluentialGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
A focus on the synapse for neuroprotection in Alzheimer disease and other dementias
Coleman, P., Federoff, H., & Kurlan, R. (2004) · Neurology · doi:10.1212/01.wnl.0000140626.48118.0a · Cited by 314
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273 · cited 2×
“These Wndings are consistent with earlier reports [11, 28, 32, 36] which show that DA quinones (DAQ) and other DA oxidation products, at concentrations of 100 M, (11) bind”
BackgroundResult
Cited by
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
“However, the most intriguing effect appears to be related to the capacity of DOPAL to induce oligomerization of a-synuclein in a cell-free system, in SH-SY5Y dopaminergic cell cultures and in vivo (Burke et al., 2008).”
Targeting Aldehyde Dehydrogenase 2: New Therapeutic Opportunities
Chen, C.-H., Ferreira, J. C. B., Gross, E. R., & Mochly-Rosen, D. (2014) · Physiological Reviews · doi:10.1152/physrev.00017.2013 · Cited by 614
Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534
Classic and New Animal Models of Parkinson's Disease
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/845618 · Cited by 505
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Masato, A., Plotegher, N., Boassa, D., & Bubacco, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0332-6 · Cited by 328
Molecular and Mechanistic Properties of the Membrane-Bound Mitochondrial Monoamine Oxidases
Edmondson, D. E., Binda, C., Wang, J., Upadhyay, A. K., & Mattevi, A. (2009) · Biochemistry · doi:10.1021/bi900413g · Cited by 300
Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis
Jain, S., & Goldstein, D. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.025 · Cited by 297
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Nitrative and Oxidative Stress in Toxicology and Disease
Roberts, R. A., Laskin, D. L., Smith, C. V., Robertson, F. M., Allen, E. M. G., Doorn, J. A., & Slikker, W. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp179 · Cited by 256
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation
Liu, G., Yu, J., Ding, J., Xie, C., Sun, L., Rudenko, I., Zheng, W., Sastry, N., Luo, J., Rudow, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72176 · Cited by 166
DNA methylation in Parkinson's disease
Wüllner, U., Kaut, O., deBoni, L., Piston, D., & Schmitt, I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13646 · Cited by 107
Jinsmaa, Y., Florang, V. R., Rees, J. N., Anderson, D. G., Strack, S., & Doorn, J. A. (2009) · Chemical Research in Toxicology · doi:10.1021/tx800405v · Cited by 106
Calcium, Bioenergetics, and Parkinson’s Disease
Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79
Wang, H., Chen, G., Ahn, E. H., Xia, Y., Kang, S. S., Liu, X., Liu, C., Han, M.-H., Chen, S., & Ye, K. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-022-00430-8 · Cited by 71
Inhibitory co-transmission from midbrain dopamine neurons relies on presynaptic GABA uptake
Melani, R., & Tritsch, N. X. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110716 · Cited by 56
Vecchio, L. M., Sullivan, P., Dunn, A. R., Bermejo, M. K., Fu, R., Masoud, S. T., Gregersen, E., Urs, N. M., Nazari, R., Jensen, P. H., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15432 · Cited by 56
“DOPAL has been shown to promote oligomerization of α- synuclein by covalent modifications of lysine residues (Burke et al. 2008; Follmer et al. 2015), and DOPAL- induced α- synuclein oligomers impede vesicular functions (Plotegher et al. 2017), potentially setting the stage for a vicious…”
BackgroundSgobio, C., Wu, J., Zheng, W., Chen, X., Pan, J., Salinas, A. G., Davis, M. I., Lovinger, D. M., & Cai, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-05598-1 · Cited by 47
Wu, Z., Xia, Y., Wang, Z., Su Kang, S., Lei, K., Liu, X., Jin, L., Wang, X., Cheng, L., & Ye, K. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0687-7 · Cited by 41
Iron Redox Chemistry and Implications in the Parkinson’s Disease Brain
Abeyawardhane, D. L., & Lucas, H. R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/4609702 · Cited by 35
“Furthermore, the aggregation is provoked by this metabolite to potentially form toxic oligomers [83].”
BackgroundBeyond Clathrin: Decoding the Mechanism of Ultrafast Endocytosis
Imoto, Y., & Watanabe, S. (2025) · Physiology · doi:10.1152/physiol.00041.2024 · Cited by 10
Metadata
- Authors
- Burke, W. J., Kumar, V. B., Pandey, N., Panneton, W. M., Gan, Q., Franko, M. W., O’Dell, M., Li, S. W., Pan, Y., Chung, H. D., & Galvin, J. E.
- Venue
- Acta Neuropathologica
- Published
- 2007-10-27
- Volume
- 115
- Issue
- 2
- Pages
- 193-203
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2109379634
- Cited by
- 243
- References
- 9
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.